# Attrition and associated factors among patients on chronic antihypertensive therapy at Mulago hospital, Uganda: A mixed method study

**Authors:** Nathan Ntenkaire, Mark Kaddu Mukasa, Patience Muwanguzi, Brian Mikka, Sandra Lunkuse, Julius Mubiru, Maxwell Okwero, Beatrice Basuuta, Douglas Bulafu, Joan N. Kalyango, Ignatius Ivan, Ignatius Ivan, Ignatius Ivan

PMC · DOI: 10.1371/journal.pone.0327933 · PLOS One · 2026-02-26

## TL;DR

This study finds that over half of patients on long-term blood pressure medication in Uganda stop attending follow-ups, with factors like location and gender playing a role.

## Contribution

The study combines quantitative and qualitative methods to identify novel factors influencing attrition in hypertension care in a low-resource setting.

## Key findings

- 56.8% of patients were lost to follow-up, with the highest attrition in 2020.
- Key factors include age, gender, residence, and blood pressure levels.
- Structural barriers and health system issues contribute to attrition.

## Abstract

Attrition among patients on chronic antihypertensive therapy is a significant problem that can lead to serious health consequences, including uncontrolled blood pressure. Several factors underlie attrition, so healthcare providers must address them to prevent treatment discontinuation and ensure optimal outcomes. Therefore, this study assessed attrition and associated factors among hypertensive patients from January 2020 and December 2022.

A sequential explanatory mixed-methods design. The quantitative study was a retrospective cohort study design using files of 1215 hypertensive patients. The qualitative study employed an explanatory descriptive design among 16 patients. A data abstraction tool and an interview guide were used for data collection. Attrition was defined as patients who were lost to follow-up. Extended Cox regression was used to determine the factors associated with time to attrition at 5% level of significance and qualitative data analysis employed a thematic analysis codebook.

The attrition proportion was 56.8% (95% confidence interval (CI) 54.0–59.7) with most patients getting lost to follow-up in 2020 (64.9%) and fewest in 2021 (54.7%). Age (hazard ratio (HR)=0.947, 95% CI 0.931–0.963), female Sex (HR = 0.734, 95% CI 0.620–0.869), residence outside Kampala (Capital City) (HR = 1.24, 95%CI 1.063–1.455), 2022 cohort entry year (HR = 1.433, 95% CI 1.156–1.777), last visit systolic blood pressure (SBP) (HR = 1.014, 95% CI 1.009–1.018), and last visit diastolic blood pressure (DBP) (HR = 0.947,95% CI 0.931–0.963) were associated with time to attrition. Loss to follow-up (LTFU) was driven by structural and contextual barriers, health system challenges, and illness perceptions and health-related limitations.

Hypertensive patient attrition proportion is high, below the Centers for Disease Control and Prevention’s 80% retention target. This calls for innovative retention strategies, and targeted support for high-risk groups like the male patients and those distant from the health facility. Patient-centered approaches addressing structural and health system barriers are essential to improving retention in hypertension care.

## Full-text entities

- **Genes:** DBP (D-box binding PAR bZIP transcription factor) [NCBI Gene 1628] {aka DABP, taxREB302}
- **Diseases:** mobility limitations (MESH:D051346), NCDs (MESH:D000073296), stroke (MESH:D020521), eye damage (MESH:D005131), cancer (MESH:D009369), diabetes (MESH:D003920), respiratory diseases (MESH:D012140), cognitive impairment (MESH:D003072), HIV (MESH:D015658), kidney disease (MESH:D007674), cardiovascular disease (MESH:D002318), COVID (MESH:D000086382), deaths (MESH:D003643), Hypertension (MESH:D006973)
- **Chemicals:** Calcium (MESH:D002118), alcohol (MESH:D000438), PONE-D-25-33575R1 (-)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12944796/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944796/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12944796/full.md

---
Source: https://tomesphere.com/paper/PMC12944796